無細胞DNA検査市場：提供、技術プラットフォーム、エンドユーザー別 - 2025年～2030年の世界予測

無細胞DNA検査市場の2024年の市場規模は67億米ドルで、2025年には71億9,000万米ドル、CAGR7.52%で成長し、2030年には103億6,000万米ドルに達すると予測されています。

無細胞DNA（cfDNA）検査は、現代の診断学において変革的なツールとして急速に台頭してきました。血液やその他の体液から微量の遺伝情報を抽出するこの技術は、極めて重要な非侵襲的検査オプションを提供するだけでなく、様々な健康状態をより早く、より正確に発見する道を開きます。今日のヘルスケア状況において、外科的介入を必要とせずに重要な遺伝子データを取得する能力は、診断方法を再定義し、様々な臨床ワークフローにおけるパラダイムシフトを促進しました。

近年、cfDNA手法の著しい進歩が見られ、腫瘍学、出生前医療、移植モニタリング、感染症検査など多様な医療分野での採用につながっています。この技術の高度化は、ニッチなアプリケーションから主流の診断資産への転換を促しました。高感度プラットフォームと革新的なシグナル検出技術の統合は、これらの検査の精度を向上させるだけでなく、ヘルスケアプロバイダーや患者の信頼性をも高めています。

この包括的な概要では、cfDNA検査が初期の期待から現在の成熟状態までどのように進化してきたかを探り、主要促進要因、市場セグメンテーション、主要地域動向について検討します。このディープダイブの目的は、急速な技術革新と臨床的期待の高まりを特徴とする環境において、この技術を活用するために必要な洞察力を業界のリーダーや意思決定者に提供することです。

無細胞DNA検査市場の変革

cfDNA検査の情勢は、急速な技術革新と臨床需要の進化に牽引され、変革の時を迎えています。過去数年の間に、分析技術とアッセイデザインにおける大きな革新が市場のアーキテクチャを再構築しました。次世代シーケンシング、マイクロ流体工学、1分子メチル化解析の統合によって可能になった感度と特異性の向上は、臨床医による早期診断と個別化治療計画へのアプローチ方法を変えつつあります。

歴史的には、侵襲的な生検法が臨床診断の主流であり、しばしば固有のリスクと限界を伴っていました。非侵襲的なcfDNA検査へのシフトは、こうしたリスクを最小限に抑えただけでなく、疾患進行の早期段階で重要な診断情報へのアクセスを拡大しました。この進化は、特に腫瘍学と出生前スクリーニングにおいて顕著であり、従来の方法では発見が遅く、介入に課題がありました。

さらに、政策の転換と規制当局の承認が市場の信頼を高め、さらなる技術革新と商業的導入に資する環境を作り出しています。政府や民間のヘルスケア機関は、疾病の罹患率と死亡率の削減においてcfDNA検査が達成できることの限界を押し広げるために、研究開発プロジェクトへの投資を増やしています。改良された分析プラットフォームと臨床検証研究の増加の融合により、cfDNA検査は精密医療の基礎技術として確立されつつあります。利害関係者がこの変化する環境を乗り切るには、この市場の将来を形作る機会と課題の両方を評価することが不可欠となります。

標的精密検査の主なセグメンテーション洞察

市場セグメンテーションを詳細に分析すると、cfDNA検査業界を支える多面的な構造が明らかになります。市場は、感染症検査、腫瘍学およびがん管理、出生前スクリーニング、移植検査を含む提供物に基づいて広範に調査されています。これらの各分野は、重要な診断ニーズに対応しています。腫瘍学とがん管理では、早期発見とスクリーニング、微小残存病変（MRD）評価に重点が置かれ、タイムリーな介入とオーダーメイドの治療レジメンが可能になります。同様に、出生前スクリーニング分野では、非侵襲的出生前検査と着床前遺伝学的検査を区別し、妊婦の両親や不妊治療の専門家に包括的な知見を提供します。

さらに、技術プラットフォームに基づく評価では、非常にダイナミックなイノベーション・エコシステムが描かれています。市場のプレーヤーは、質量分析、マイクロ流体工学から核酸技術、ポリメラーゼ連鎖反応（PCR）、1分子メチル化まで、さまざまな技術的アプローチを活用しています。このような技術的応用の多様性は、分析精度と業務効率の向上へのコミットメントを強調するものです。

さらに、エンドユーザーに基づくセグメンテーションは、病院や診療所とは対照的に、診断研究所や検査センターの明確なニーズを浮き彫りにしています。各エンドユーザー・セグメントは、その運営規模や臨床専門性に合わせたソリューションを求めており、カスタマイズ可能で統合的な検査プロトコルの必要性を推進しています。このようなセグメンテーションのニュアンスを理解することは、成長機会を特定し、臨床面および業務面における多様な利害関係者の進化する要求に沿った戦略を設計するための鍵となります。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 非侵襲的検査の利点に関する消費者と医師の意識の高まり
    • 胎児異常をより安全かつ早期に発見するための非侵襲的出生前検査の需要が高まっている
    • ゲノム技術の臨床調査の拡大
  • 抑制要因
    • シーケンシング技術の高コストにより、細胞フリーDNA診断へのアクセスが減少
  • 機会
    • ヘルスケアの近代化と精密医療を優先する政策への政府の投資
    • 個別化医療戦略の採用の増加により、治療計画を導くための重要な選択肢が生まれています。
  • 課題
    • 機密性の高い遺伝情報に関するデータのプライバシーとセキュリティに関する懸念
• 市場セグメンテーション分析
  • 提供：感染症検査の活用による迅速な検出と管理の支援
  • エンドユーザー：高スループット操作に重点を置いているため、診断ラボが好まれる
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 無細胞DNA検査市場：提供別

• 感染症検査
• 腫瘍学とがん管理
  • 早期発見とスクリーニング
  • 微小残存病変（MRD）評価
• 出生前スクリーニング
  • 非侵襲的出生前検査
  • 着床前遺伝子検査
• 移植検査

第7章 無細胞DNA検査市場：技術プラットフォーム別

• 質量分析
• マイクロ流体
• 核酸技術
• ポリメラーゼ連鎖反応（PCR）
• 単一分子メチル化

第8章 無細胞DNA検査市場：エンドユーザー別

• 診断研究所および検査センター
• 病院・クリニック

第9章 南北アメリカの無細胞DNA検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の無細胞DNA検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの無細胞DNA検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Adaptive Biotechnologies Corporation
• Agilent Technologies, Inc.
• BGI Genomics Co., Ltd.
• Biodesix, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche
• Fulgent Genetics, Inc.
• Guardant Health, Inc.
• Laboratory Corporation of America Holdings
• llumina, Inc.
• Myriad Genetics, Inc.
• Natera, Inc.
• OPKO Health, Inc.
• PerkinElmer, Inc.
• Qiagen N.V.
• Revvity, Inc
• SOPHiA GENETICS AG
• Stilla Technologies
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. CELL-FREE DNA TESTING MARKET MULTI-CURRENCY
• FIGURE 2. CELL-FREE DNA TESTING MARKET MULTI-LANGUAGE
• FIGURE 3. CELL-FREE DNA TESTING MARKET RESEARCH PROCESS
• FIGURE 4. CELL-FREE DNA TESTING MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 15. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 17. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. CELL-FREE DNA TESTING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 23. CELL-FREE DNA TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CELL-FREE DNA TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELL-FREE DNA TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY INFECTIOUS DISEASES TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY EARLY DETECTION AND SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TRANSPLANTATION TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY NUCLEIC ACID TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY SINGLE-MOLECULE METHYLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES & TESTING CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 44. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 45. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 46. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 47. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 71. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 72. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 73. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 74. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 76. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 77. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 78. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 79. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 162. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 163. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 164. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 165. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 182. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 183. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 184. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 185. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 187. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 188. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 189. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 190. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. CELL-FREE DNA TESTING MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 237. CELL-FREE DNA TESTING MARKET, FPNV POSITIONING MATRIX, 2024

The Cell-Free DNA Testing Market was valued at USD 6.70 billion in 2024 and is projected to grow to USD 7.19 billion in 2025, with a CAGR of 7.52%, reaching USD 10.36 billion by 2030.

Cell-free DNA (cfDNA) testing has rapidly emerged as a transformative tool within modern diagnostics. This technology, which extracts minute amounts of genetic information from blood or other bodily fluids, not only offers pivotal non-invasive testing options but also paves the way for earlier and more accurate detection of a range of health conditions. In today's healthcare landscape, the ability to capture vital genetic data without the need for surgical interventions has redefined diagnostic practices, fostering a paradigm shift across various clinical workflows.

Recent years have witnessed significant advancements in cfDNA methodologies, leading to its adoption across diverse medical fields including oncology, prenatal care, transplantation monitoring, and infectious disease testing. The growing sophistication of this technology has catalyzed its shift from a niche application to a mainstream diagnostic asset. The integration of high sensitivity platforms and innovative signal detection techniques has not only enhanced the accuracy of these tests but also boosted confidence among healthcare providers and patients alike.

In this comprehensive overview, we explore how cfDNA testing has evolved from its early promise to a current state of maturity, examining key drivers, market segmentations, and leading regional trends. This deep dive aims to equip industry leaders and decision-makers with the insights required to harness this technology in an environment characterized by rapid innovation and heightened clinical expectations.

Transformative Shifts in the Cell-Free DNA Testing Landscape

The landscape of cfDNA testing is undergoing transformative shifts driven by rapid technological advancements and evolving clinical demand. Over the past few years, significant innovations in analytical techniques and assay designs have reshaped the market's architecture. Enhanced sensitivity and specificity, enabled by the integration of next-generation sequencing, microfluidics, and single-molecule methylation analysis, are changing the way clinicians approach early diagnosis and personalized treatment plans.

Historically, invasive biopsy procedures dominated clinical diagnostics, often accompanied by inherent risks and limitations. The shift towards non-invasive cfDNA testing has not only minimized these risks but has also expanded access to critical diagnostic information at earlier stages of disease progression. This evolution is particularly notable in oncology and prenatal screening, where traditional methods have long struggled with late detection and intervention challenges.

Additionally, policy shifts and regulatory approvals have bolstered market confidence, creating an environment conducive to further innovations and commercial adoption. Government and private healthcare entities are increasingly investing in research and development projects to push the boundaries of what cfDNA testing can achieve in reducing disease morbidity and mortality. The convergence of improved analytical platforms and a growing body of clinical validation studies is establishing cfDNA testing as a cornerstone technology in precision medicine. As stakeholders navigate this changing milieu, it becomes imperative to assess both the opportunities and challenges that are shaping this market's future.

Key Segmentation Insights for Targeted and Precision Testing

A granular analysis of market segmentation reveals a multifaceted structure underpinning the cfDNA testing industry. The market is extensively studied based on offerings, which include infectious diseases testing, oncology and cancer management, prenatal screening, and transplantation testing. Each of these areas addresses critical diagnostics needs. In oncology and cancer management, the focus extends further to early detection and screening as well as minimal residual disease (MRD) assessment, allowing for timely intervention and tailored treatment regimens. Similarly, the prenatal screening segment differentiates between non-invasive prenatal testing and preimplantation genetic testing, providing comprehensive insights for expectant parents and fertility specialists.

Moreover, an evaluation based on technology platforms paints a picture of a highly dynamic innovation ecosystem. Market players leverage a range of technological approaches, from mass spectrometry and microfluidics to nucleic acid technology, polymerase chain reaction (PCR), and single-molecule methylation. This diversity in technological application underlines the commitment to enhancing analytical precision and operational efficiency.

Furthermore, the segmentation based on end-users highlights the distinct needs of diagnostic laboratories and testing centers in contrast to hospitals and clinics. Each end-user segment demands solutions tailored to its operational scale and clinical expertise, driving the necessity for customizable and integrative testing protocols. Understanding these segmentation nuances is key to identifying growth opportunities and designing strategies that align with the evolving demands of diverse stakeholders on the clinical and operational fronts.

Based on Offerings, market is studied across Infectious Diseases Testing, Oncology & Cancer Management, Prenatal Screening, and Transplantation Testing. The Oncology & Cancer Management is further studied across Early Detection and Screening and Minimal Residual Disease (MRD) Assessment. The Prenatal Screening is further studied across Non-Invasive Prenatal Testing and Preimplantation Genetic Testing.

Based on Technology Platform, market is studied across Mass Spectrometry, Microfluidics, Nucleic Acid Technology, Polymerase chain reaction (PCR), and Single-molecule Methylation.

Based on End-User, market is studied across Diagnostic Laboratories & Testing Centers and Hospitals & Clinics.

Regional Dynamics: Navigating Global Opportunities and Challenges

Globally, the adoption and evolution of cfDNA testing exhibit varied trends across different regions, each characterized by unique healthcare landscapes and regulatory environments. In the Americas, robust investments in healthcare infrastructure combined with an increasing focus on preventive care have accelerated the integration of cfDNA testing into routine clinical practices. Here, the market benefits from high levels of technological adoption and proactive patient engagement, creating an ecosystem where early diagnosis and personalized medicine are becoming the norm.

The Europe, Middle East & Africa region presents a diverse picture. European markets, with their advanced healthcare systems and regulatory frameworks, have been at the forefront of adopting cutting-edge diagnostic technologies. Simultaneously, emerging markets in the Middle East and Africa are increasingly recognizing the potential of cfDNA testing, driven by rising healthcare demands and initiatives aimed at modernizing diagnostic services. Such dynamics are fostering collaborations between public and private sectors, ensuring that the benefits of early and non-invasive testing reach broader populations.

In the Asia-Pacific region, rapid economic growth and expanding healthcare access are fueling significant market expansion. Countries within this region are investing heavily in technology-driven healthcare solutions, including cfDNA testing. This growth is bolstered by favorable governmental policies, increased R&D activities, and strong collaborations with international biotech companies. While regions continue to face distinct challenges related to infrastructure and regulatory clarity, the underlying momentum towards innovation presents ample opportunities for market players aiming to harness the full potential of cfDNA testing.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Players: Market Innovators and Strategic Movers

The competitive landscape in the cfDNA testing market is marked by the presence of several key industry players who are driving innovation and setting new benchmarks. Companies such as Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., and BGI Genomics Co., Ltd. have been instrumental in developing advanced testing protocols and expanding market access through robust distribution networks. Their continuous investment in research and development is a testament to their commitment to advancing cfDNA technologies.

Further, prominent organizations including Biodesix, Inc., Bio-Rad Laboratories, Inc., and F. Hoffmann-La Roche are spearheading initiatives that integrate advanced computational analytics with cutting-edge diagnostic tools, bringing enhanced precision to early detection and disease monitoring. Fulgent Genetics, Inc., Guardant Health, Inc., and Laboratory Corporation of America Holdings are also recognized leaders, utilizing their expansive global outreach to deliver reliable non-invasive diagnostic solutions. The market also benefits from the expertise of llumina, Inc., Myriad Genetics, Inc., Natera, Inc., and OPKO Health, Inc., who have all contributed significantly to the evolution of cfDNA testing methodologies.

Additional market momentum is derived from the initiatives of PerkinElmer, Inc., Qiagen N.V., Revvity, Inc, SOPHiA GENETICS AG, Stilla Technologies, and Thermo Fisher Scientific, Inc. These organizations are known for their innovative approaches, especially in integrating advanced technology platforms such as microfluidics and PCR-based systems. The diversified strengths of these companies not only bolster overall market credibility but also stimulate competitive differentiation and continuous improvements in testing efficacy and turnaround times. Their strategic movements reflect a deep understanding of market needs and a proactive approach to overcoming clinical and operational challenges.

The report delves into recent significant developments in the Cell-Free DNA Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., BGI Genomics Co., Ltd., Biodesix, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche, Fulgent Genetics, Inc., Guardant Health, Inc., Laboratory Corporation of America Holdings, llumina, Inc., Myriad Genetics, Inc., Natera, Inc., OPKO Health, Inc., PerkinElmer, Inc., Qiagen N.V., Revvity, Inc, SOPHiA GENETICS AG, Stilla Technologies, and Thermo Fisher Scientific, Inc.. Actionable Recommendations for Industry Leaders

Industry leaders stand at the nexus of innovation and market transformation. It is crucial to adopt an integrative strategy that blends technological advancements with insights drawn from comprehensive market segmentation. Leaders should prioritize investment in cutting-edge analytical platforms while embracing cross-sector collaborations, thereby enhancing the accuracy and reliability of cfDNA testing. Strategic partnerships with technology innovators and clinical research institutions can also bridge the gap between emerging diagnostic capabilities and established healthcare practices.

In addition, focusing on personalized diagnostic approaches will not only cater to the specific demands of various patient populations but also secure a competitive edge in a rapidly evolving market. It is advisable to continuously monitor regulatory developments and leverage data-driven insights to optimize test deployment strategies, ensuring adaptable and scalable solutions that meet both current and future market needs.

Conclusion: Synthesis and Future Outlook

The journey of cfDNA testing from an experimental diagnostic tool to a mainstream clinical asset underscores its transformative potential. The convergence of technological innovations, diverse market segmentations, and dynamic regional trends is reshaping diagnostic paradigms across the globe. Insights into specific market segments, technological platforms, and end-user demands illustrate a landscape characterized by both opportunity and complexity.

As the market continues its upward trajectory, stakeholders are encouraged to adopt forward-thinking approaches that integrate advanced analytics, collaborative ventures, and strategic foresight. The future of cfDNA testing is promising, with sustained advancements poised to further enhance the scope of non-invasive diagnostics and contribute to improved clinical outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising consumer and physician awareness regarding non-invasive testing benefits
    • 5.1.1.2. Growing demand for non-invasive prenatal testing to ensure safer and earlier detection of fetal abnormalities
    • 5.1.1.3. Expanding clinical research in genomic technologies
  • 5.1.2. Restraints
    • 5.1.2.1. High costs of sequencing technology reducing accessibility for cell free DNA diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Government investments in healthcare modernization and policies favoring precision medicine
    • 5.1.3.2. Increasing adoption of personalized medicine strategies is creating significant options for guiding treatment planning
  • 5.1.4. Challenges
    • 5.1.4.1. Data privacy and security concerns related to sensitive genetic information
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offerings: Utilization of infectious disease testing for rapid detection and aiding in the management
  • 5.2.2. End-User: Preference for diagnostic laboratories due to their focus on high-throughput operations
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cell-Free DNA Testing Market, by Offerings

• 6.1. Introduction
• 6.2. Infectious Diseases Testing
• 6.3. Oncology & Cancer Management
  • 6.3.1. Early Detection and Screening
  • 6.3.2. Minimal Residual Disease (MRD) Assessment
• 6.4. Prenatal Screening
  • 6.4.1. Non-Invasive Prenatal Testing
  • 6.4.2. Preimplantation Genetic Testing
• 6.5. Transplantation Testing

7. Cell-Free DNA Testing Market, by Technology Platform

• 7.1. Introduction
• 7.2. Mass Spectrometry
• 7.3. Microfluidics
• 7.4. Nucleic Acid Technology
• 7.5. Polymerase chain reaction (PCR)
• 7.6. Single-molecule Methylation

8. Cell-Free DNA Testing Market, by End-User

• 8.1. Introduction
• 8.2. Diagnostic Laboratories & Testing Centers
• 8.3. Hospitals & Clinics

9. Americas Cell-Free DNA Testing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cell-Free DNA Testing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cell-Free DNA Testing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. FPNV Positioning Matrix, 2024
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Aldevron unveils alchemy, a rapid, purified cell-free DNA technology
  • 12.3.2. Natera expands reproductive health testing with strategic acquisition
  • 12.3.3. Natera secures USD 250M to accelerate personalized cfDNA testing
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Adaptive Biotechnologies Corporation
• 3. Agilent Technologies, Inc.
• 4. BGI Genomics Co., Ltd.
• 5. Biodesix, Inc.
• 6. Bio-Rad Laboratories, Inc.
• 7. F. Hoffmann-La Roche
• 8. Fulgent Genetics, Inc.
• 9. Guardant Health, Inc.
• 10. Laboratory Corporation of America Holdings
• 11. llumina, Inc.
• 12. Myriad Genetics, Inc.
• 13. Natera, Inc.
• 14. OPKO Health, Inc.
• 15. PerkinElmer, Inc.
• 16. Qiagen N.V.
• 17. Revvity, Inc
• 18. SOPHiA GENETICS AG
• 19. Stilla Technologies
• 20. Thermo Fisher Scientific, Inc.